NCT00697970已完成3 期
Study to Evaluate the Immunogenicity and Reactogenicity of Various Formulations of GSK Biologicals' (Previously SmithKline Beecham Biologicals') Recombinant Hepatitis B Vaccine in Healthy Adult Volunteers
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 321
- 试验地点
- 1
- 主要终点
- Anti-HBs antibody concentrations
研究概览
简要总结
The purpose of the present trial is to evaluate 6 vaccine formulations of recombinant hepatitis B vaccine for their reactogenicity and immunogenicity when administered at 0-2 months with a booster at month 12
详细描述
At the time of conduct of this study, the sponsor GlaxoSmithKline was known by its former name SmithKline Beecham
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 40 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Between 18 and 40 years old.
- •Written informed consent will have been obtained from the subjects.
- •Good physical condition as established by physical examination and history taking at the time of entry.
- •Female participants will avoid becoming pregnant during the study period and they will have been on a contraceptive program for at least 2 months before entry.
排除标准
- •Pregnancy or lactation.
- •Positivity for anti hepatitis antibodies.
- •Any vaccination against hepatitis B in the past.
- •Any previous administration of MPL.
- •Elevated serum liver enzymes.
- •History of significant and persisting hematologic, hepatic, renal, cardiac or respiratory disease.
- •Axillary temperature > 37.5°C at the time of injection.
- •Any acute disease at the moment of entry.
- •Chronic alcohol consumption.
- •Any treatment with immunosuppressive or immunostimulant therapy.
- •Any chronic drug treatment, which in the investigator's opinion, precludes inclusion into the study.
- •History of allergic disease likely to be stimulated by any component of the vaccine.
- •Administration of any other vaccine(s) or any immunoglobulin during the study period.
- •Simultaneous participation in any other clinical trial
结局指标
主要结局
Anti-HBs antibody concentrations
时间窗: After two doses and after the booster dose
次要结局
- Occurrence and intensity of local and general solicited symptoms(8 days after vaccination)
- Anti-HBs antibody concentrations(Screening, M1, 2, 3, 4, 6, 12, 13)
- Occurrence of unsolicited adverse events(30-day after vaccination)
- Occurrence of serious adverse events(During the study period and 30 days after the last vaccination)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Clinical Trial of Recombinant Hepatitis B Vaccine (Hansenula Polymorpha, 10μg)Hepatitis BNCT04075201Sinovac Biotech Co., Ltd144
已完成
3 期
Comparison of Immuno, Reacto and Safety of Recombinant Hepatitis B Vaccine With or Without MPL in Healthy Older AdultsHepatitis BNCT00697242GlaxoSmithKline362
Unknown
4 期
Adolescents' Response to Hepatitis B Vaccine Booster DoseHepatitis BNCT01341275Baylor College of Medicine400
已完成
2 期
Comparing Immunogenicity and Safety of Different Formulations of HBV-MPL Vaccine With Engerix™-B in Adults Aged 18-40 yHepatitis BNCT00698555GlaxoSmithKline163
已完成
4 期
Immunogenicity of 2 Versus 3 Doses of Combined Hepatitis B Vaccines in 2-18 Months Old ChildrenHepatitis BNCT04294433Laval University431